Blood Test Guides Post-Surgical Immunotherapy for Muscle-Invasive Bladder Cancer

Blood test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ctDNA-negative patients may potentially be spared unnecessary treatment. The finding is based on results from the global, randomized, phase 3 IMvigor011 trial co-led by investigators from Dana-Farber Cancer Institute, the Technical University of Mu…

IMvigor011: ctDNA-Guided Atezolizumab Boosts DFS/OS in MIBC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Atezolizumab significantly enhances disease-free and overall survival in ctDNA-positive muscle-invasive bladder cancer patients, reshaping treatment strategies.

ctDNA-guided atezolizumab boosts survival in muscle-invasive bladder cancer

In patients who were ctDNA positive, median DFS was 9.9 months (95% CI: 7.2-12.7) in the atezolizumab group vs 4.8 months (95% CI: 4.1-8.3) in the placebo group.

Roche Announces Landmark IMvigor011 Results Showing Tecentriq Significantly Improves Survival in Muscle-Invasive Bladder Cancer Using ctDNA-Guided Treatment

Open the article to view the coverage from EuropaWire.eu